Huda Y. Zoghbi
CIK: 0001681643
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
REGENERON PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (16 total)
- Aug 10, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct800 shares at avg. $800.00$640K - Aug 10, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Exercise(M)Direct800 shares at avg. $376.69$301K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct49 shares at avg. $774.68$38K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct50 shares at avg. $775.50$39K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct53 shares at avg. $778.47$41K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct208 shares at avg. $779.55$162K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct331 shares at avg. $780.45$258K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct209 shares at avg. $781.28$163K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct298 shares at avg. $782.10$233K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct220 shares at avg. $783.29$172K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct160 shares at avg. $784.45$126K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct56 shares at avg. $785.61$44K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Sale(S)Direct4 shares at avg. $790.00$3K - Feb 19, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Exercise(M)Direct1.6K shares at avg. $376.69$617K - Jan 2, 2026REGN
REGENERON PHARMACEUTICALS, INC.
Award(A)Direct155 shares- - Jan 2, 2025REGN
REGENERON PHARMACEUTICALS, INC.
Award(A)Direct166 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 800 | $800.00 | $640,000 | Direct |
| Aug 10, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Exercise(M) | 800 | $376.69 | $301,352 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 49 | $774.68 | $37,959 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 50 | $775.50 | $38,775 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 53 | $778.47 | $41,259 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 208 | $779.55 | $162,146 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 331 | $780.45 | $258,329 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 209 | $781.28 | $163,288 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 298 | $782.10 | $233,066 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 220 | $783.29 | $172,324 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 160 | $784.45 | $125,512 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 56 | $785.61 | $43,994 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Sale(S) | 4 | $790.00 | $3,160 | Direct |
| Feb 19, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Exercise(M) | 1,638 | $376.69 | $617,018 | Direct |
| Jan 2, 2026 | REGN REGENERON PHARMACEUTICALS, INC. | Award(A) | 155 | - | $0 | Direct |
| Jan 2, 2025 | REGN REGENERON PHARMACEUTICALS, INC. | Award(A) | 166 | - | $0 | Direct |
1-16 of 16 transactions
About Zoghbi Huda Y
Zoghbi Huda Y (SEC CIK 0001681643) files insider reports with the SEC as Director of REGENERON PHARMACEUTICALS, INC. (REGN).
Signal8 holds 4 ownership filings by Zoghbi Huda Y, all Form 4s, filed between Jan 6, 2025 and Aug 12, 2026. Those filings report 16 transactions, from Jan 2, 2025 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Zoghbi Huda Y's filings is in TARRYTOWN, NY.
Recent filings by Zoghbi Huda Y
- Aug 10, 2026: Open-market sale of REGN shares (Form 4, code S).
- Aug 10, 2026: Option exercise of REGN shares (Form 4, code M).
- Feb 19, 2026: Open-market sales of REGN shares (11 lines, Form 4, code S).
- Feb 19, 2026: Option exercise of REGN shares (Form 4, code M).
- Jan 2, 2026: Grant or award of REGN shares (Form 4, code A).
Other insiders filing for REGENERON PHARMACEUTICALS, INC. (REGN)
- Guarini Kathryn, Director
- BROWN MICHAEL S, Director
- McCourt Marion, EVP Commercial
- MURPHY ANDREW J, Co-Chief Scientific Officer
- LAROSA JOSEPH J, EVP General Counsel and Secret
- Fenimore Christopher R., EVP Finance CFO